BR112023026510A2 - Composições e seu uso para o tratamento de deficiência de alfa1-antitripsina - Google Patents

Composições e seu uso para o tratamento de deficiência de alfa1-antitripsina

Info

Publication number
BR112023026510A2
BR112023026510A2 BR112023026510A BR112023026510A BR112023026510A2 BR 112023026510 A2 BR112023026510 A2 BR 112023026510A2 BR 112023026510 A BR112023026510 A BR 112023026510A BR 112023026510 A BR112023026510 A BR 112023026510A BR 112023026510 A2 BR112023026510 A2 BR 112023026510A2
Authority
BR
Brazil
Prior art keywords
alpha1
treatment
compositions
deficiency
antitripsin
Prior art date
Application number
BR112023026510A
Other languages
English (en)
Portuguese (pt)
Inventor
John Fox David
Andrew Huntington James
Nigel Ramsden
Original Assignee
Centessa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals Uk Ltd filed Critical Centessa Pharmaceuticals Uk Ltd
Publication of BR112023026510A2 publication Critical patent/BR112023026510A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112023026510A 2021-06-15 2022-06-15 Composições e seu uso para o tratamento de deficiência de alfa1-antitripsina BR112023026510A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108523.8A GB202108523D0 (en) 2021-06-15 2021-06-15 Compositions and their use for the treatment of alpha1-antitrypsin deficiency
PCT/GB2022/051502 WO2022263816A1 (en) 2021-06-15 2022-06-15 COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
BR112023026510A2 true BR112023026510A2 (pt) 2024-03-05

Family

ID=76954605

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023026510A BR112023026510A2 (pt) 2021-06-15 2022-06-15 Composições e seu uso para o tratamento de deficiência de alfa1-antitripsina

Country Status (12)

Country Link
US (1) US12673050B2 (enExample)
EP (1) EP4355328A1 (enExample)
JP (1) JP7854001B2 (enExample)
KR (1) KR20240027693A (enExample)
CN (1) CN117794538A (enExample)
AU (1) AU2022295130A1 (enExample)
BR (1) BR112023026510A2 (enExample)
CA (1) CA3223130A1 (enExample)
GB (1) GB202108523D0 (enExample)
IL (1) IL309355A (enExample)
MX (1) MX2023015398A (enExample)
WO (1) WO2022263816A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
JP3391038B2 (ja) 1991-12-26 2003-03-31 富士レビオ株式会社 カルボン酸アミド誘導体
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US8258158B2 (en) 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
WO2012097371A2 (en) * 2011-01-14 2012-07-19 The Regents Of The University Of California Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
CN110325527B (zh) 2016-12-09 2022-08-09 勃林格殷格翰国际有限公司 作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺
CA3103920C (en) 2018-06-22 2025-09-16 Ucl Business Ltd COMPOUNDS FOR TREATING DISEASES MEDIATED BY ALPHA-1 ANTITRYPSIN
JOP20210060A1 (ar) 2018-10-05 2023-01-30 Vertex Pharma معدلات لمضاد تريبسين ألفا-1
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB201918410D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Also Published As

Publication number Publication date
JP7854001B2 (ja) 2026-04-30
US12673050B2 (en) 2026-07-07
JP2024523406A (ja) 2024-06-28
US20240197707A1 (en) 2024-06-20
AU2022295130A1 (en) 2024-01-18
MX2023015398A (es) 2024-04-29
GB202108523D0 (en) 2021-07-28
CN117794538A (zh) 2024-03-29
KR20240027693A (ko) 2024-03-04
CA3223130A1 (en) 2022-12-22
IL309355A (en) 2024-02-01
EP4355328A1 (en) 2024-04-24
WO2022263816A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
BR112017017009A2 (pt) usos de um sequestrante de formaldeído e de uma composição farmacêutica, métodos para impedir, adiar, retardar ou diminuir a transformação de um composto e para tratar câncer, e, composição farmacêutica.
BR112013012740A2 (pt) sais e formas cristalinas de um agente que induz apoptose
BR112021023814A2 (pt) Inibidores de proteases de cisteína e métodos de uso das mesmas
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
BR112013006030A2 (pt) composto e sais, solvatos, n-óxidos ou prodrogas farmaceuticamente aceitáveis, composição farmacêutica, uso do composto, kit, método de tratamento de uma doença, e, composição anti-helmíntica
MX382665B (es) 1,2,4-triazolonas 2,4,5-trisustituidas.
ES3064032T3 (en) Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies
EA201100312A1 (ru) Антимикробные агенты
BRPI0909749A2 (pt) uso de fotoiniciador para fabrico de medicamento para tratamento do ceratocone, da ectasia e fortalecimento da córnea
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
BR112015019412A2 (pt) inibidores de bace1
BR112017021024A2 (pt) novos usos farmacêuticos
MX2023009388A (es) Metodos para tratar alteraciones del comportamiento.
BR112014006223A2 (pt) 6-substituídas-3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas como tirosina quinase c-met
AR048439A1 (es) Composiciones farmaceuticas y metodos para tratar la infeccion por vih
PY2295067A (es) Inhibidores del sars-cov-2 para tratar infecciones por coronavirus
MX2023015398A (es) Composiciones y su uso para el tratamiento de la deficiencia de a1-antitripsina.
CO2023005726A2 (es) Formulación sólida
MX2024003015A (es) Nuevos derivados de quinolina.
JOP20240197A1 (ar) أشكال متعددة من الأتيكابرانت للاستخدام في علاج اضطراب الاكتئاب الشديد
MX2022007176A (es) 4-((2-oxopyri din-1 (2h)-yl)metil)benzamidas para el tratamiento de la deficiencia de alfa1-antitripsina.
MX2022007174A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
BR112022011566A2 (pt) Compostos e uso dos mesmos para o tratamento de deficiência de a1-antitripsina
CO2025016290A2 (es) Compuestos anti-vih